Finding the right balance: aOX40 immunotherapy enhances effector T cell function without impairing regulatory T cells intrinsic suppressive capacity in mouse tumor models

Ítems similars

• OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression
  per: Moran, Amy, et al.
  Publicat: (2014)
• The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
  per: Moran, Amy E., et al.
  Publicat: (2013)
• OX40-enhanced tumor rejection and effector T cell differentiation decreases with age
  per: Ruby, Carl E., et al.
  Publicat: (2009)
• Immunotherapy expands and maintains the function of high affinity tumor infiltrating CD8 T cells in situ
  per: Moran, Amy E., et al.
  Publicat: (2016)
• Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression
  per: Yu, Guangjie, et al.
  Publicat: (2016)